1. Home
  2. VRAX vs POAI Comparison

VRAX vs POAI Comparison

Compare VRAX & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.39

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Predictive Oncology Inc.

POAI

Predictive Oncology Inc.

HOLD

Current Price

$5.95

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
POAI
Founded
2013
2002
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
6.5M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VRAX
POAI
Price
$0.39
$5.95
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
15.4M
42.7K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,986.00
$1,664,407.00
Revenue This Year
$217,274.83
$486.27
Revenue Next Year
N/A
$65.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
320.71
52 Week Low
$0.35
$3.88
52 Week High
$3.20
$45.90

Technical Indicators

Market Signals
Indicator
VRAX
POAI
Relative Strength Index (RSI) 40.57 47.30
Support Level $0.39 $3.88
Resistance Level $0.43 $6.25
Average True Range (ATR) 0.07 0.76
MACD -0.01 0.11
Stochastic Oscillator 1.23 79.01

Price Performance

Historical Comparison
VRAX
POAI

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About POAI Predictive Oncology Inc.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Share on Social Networks: